Tammy Owens, NP
Psychiatric/Mental Health · Buffalo, NYNPI 1306098249
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,603 of the $7,503 with a category attached, or 88.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,138 and has fallen 89.0% since, to $344 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $51.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$966
- Otsuka America Pharmaceutical, Inc.$745
- Idorsia Pharmaceuticals US Inc$720
- Teva Pharmaceuticals USA, Inc.$719
- plus $2K from 11 others
What the payments were for
- Consulting fees$72010%
- Food & beverage$6,60388%
- Education$1802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 23 | $1,347 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $1,010 |
| Alkermes, Inc. | 21 | $966 |
| Otsuka America Pharmaceutical, Inc. | 11 | $745 |
| Idorsia Pharmaceuticals US Inc | 1 | $720 |
| Teva Pharmaceuticals USA, Inc. | 12 | $719 |
| AbbVie | 25 | $711 |
| Neurocrine Biosciences, Inc. | 4 | $273 |
| E.r. Squibb & Sons, L.L.C. | 2 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Corium, LLC | 1 | $125 |
| Grifols USA, LLC | 1 | $120 |
| Novo Nordisk | 1 | $120 |
| Gilead | 1 | $115 |
| Axsome Therapeutics, Inc. | 1 | $112 |
| Almatica Pharma LLC | 3 | $66 |
| Lundbeck LLC | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$948
- LYBALVI$867
- QUVIVIQ$720
- INVEGA SUSTENNA$531
- VRAYLAR$460
- REXULTI$350
- CAPLYTA$342
- ABILIFY ASIMTUFII$258
- ABILIFY MAINTENA$258
- AUSTEDO$250
- ARISTADA INITIO$237
- INGREZZA$234
- SPRAVATO$137
- Azstarys$125
- UZEDY$125
- Prolastin-C Liquid$120
- Erleada$119
- COBENFY$118
- Epclusa$115
- Auvelity$112
How this compares
$7,503 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 18 | $10,213 |
| TrintellixVortioxetine Hydrobromide | 12 | $7,367 |
| Paliperidone ErPaliperidone | 28 | $3,632 |
| Aripiprazole | 41 | $2,162 |
| Vilazodone Hcl | 15 | $1,680 |
| Quetiapine Fumarate | 51 | $1,204 |
| Clonazepam | 119 | $1,159 |
| Alprazolam | 45 | $838 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $673 |
| Duloxetine Hcl | 45 | $669 |
| Tetrabenazine | 13 | $602 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $460 |
| Lamotrigine | 37 | $456 |
| Escitalopram Oxalate | 73 | $358 |
| Hydroxyzine Hcl | 19 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $132 | $17,58030 claims |
| Almatica Pharma LLCSertraline Hcl | $66 | $17127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Buffalo
- Carl de FrancoBuffalo$28K
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.